JP2023518543A5 - - Google Patents

Info

Publication number
JP2023518543A5
JP2023518543A5 JP2022556248A JP2022556248A JP2023518543A5 JP 2023518543 A5 JP2023518543 A5 JP 2023518543A5 JP 2022556248 A JP2022556248 A JP 2022556248A JP 2022556248 A JP2022556248 A JP 2022556248A JP 2023518543 A5 JP2023518543 A5 JP 2023518543A5
Authority
JP
Japan
Prior art keywords
alkyl
group
optionally substituted
halogen
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022556248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518543A (ja
JP7856575B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/023228 external-priority patent/WO2021188944A1/en
Publication of JP2023518543A publication Critical patent/JP2023518543A/ja
Publication of JP2023518543A5 publication Critical patent/JP2023518543A5/ja
Application granted granted Critical
Publication of JP7856575B2 publication Critical patent/JP7856575B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022556248A 2020-03-20 2021-03-19 Phd阻害剤化合物、組成物、及びそれらの使用 Active JP7856575B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062992616P 2020-03-20 2020-03-20
US62/992,616 2020-03-20
PCT/US2021/023228 WO2021188944A1 (en) 2020-03-20 2021-03-19 Phd inhibitor compounds, compositions, and their use

Publications (3)

Publication Number Publication Date
JP2023518543A JP2023518543A (ja) 2023-05-02
JP2023518543A5 true JP2023518543A5 (cg-RX-API-DMAC10.html) 2024-05-29
JP7856575B2 JP7856575B2 (ja) 2026-05-11

Family

ID=75478265

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022556248A Active JP7856575B2 (ja) 2020-03-20 2021-03-19 Phd阻害剤化合物、組成物、及びそれらの使用

Country Status (7)

Country Link
US (1) US12703691B2 (cg-RX-API-DMAC10.html)
EP (1) EP4121424A1 (cg-RX-API-DMAC10.html)
JP (1) JP7856575B2 (cg-RX-API-DMAC10.html)
CN (2) CN120004851A (cg-RX-API-DMAC10.html)
AR (1) AR121626A1 (cg-RX-API-DMAC10.html)
TW (1) TWI917364B (cg-RX-API-DMAC10.html)
WO (1) WO2021188944A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US12612367B2 (en) 2019-12-10 2026-04-28 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
AR121626A1 (es) 2020-03-20 2022-06-22 Akebia Therapeutics Inc Compuestos inhibidores de phd, composiciones y métodos de uso
JP2025500892A (ja) * 2021-12-17 2025-01-15 アケビア セラピューティクス インコーポレイテッド 選択的phd1阻害剤化合物、組成物、及び使用方法
CN118745146B (zh) * 2024-06-24 2025-09-23 上海坦泰生物科技有限公司 一种5-氟-2-肼基吡啶二盐酸盐的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663327A (en) * 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (de) * 1984-11-28 1986-05-28 Bayer Ag, 5090 Leverkusen 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
DE3527157A1 (de) 1985-07-30 1987-02-12 Bayer Ag 1-heteroaryl-4-aryl-pyrazol-derivate
DE4023488A1 (de) 1990-07-24 1992-01-30 Bayer Ag 1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide
CA2138929A1 (en) 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
CN102351791B (zh) 2006-01-27 2014-10-29 菲布罗根有限公司 使低氧诱导因子(hif)稳定的氰基异喹啉化合物
NZ623002A (en) 2006-06-26 2015-08-28 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
US20090011051A1 (en) 2006-09-28 2009-01-08 Roth Mark B Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
DE102006050512A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte heterocyclische Verbindungen und ihre Verwendung
DE102006050516A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
DE102007044032A1 (de) * 2007-09-14 2009-03-19 Bayer Healthcare Ag Substituierte heterocyclische Verbindungen und ihre Verwendung
WO2010005851A1 (en) * 2008-07-08 2010-01-14 Xenon Pharmaceuticals Inc. Combination therapy for treating iron disorders
SG172803A1 (en) 2008-12-29 2011-08-29 Sanofi Sa Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof as hif activators
NO2686520T3 (cg-RX-API-DMAC10.html) 2011-06-06 2018-03-17
WO2013134660A1 (en) 2012-03-09 2013-09-12 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
US8987461B2 (en) * 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
AP2015008783A0 (en) 2013-03-29 2015-10-31 Takeda Pharmaceutical 6-(5-hydroxy-1h-pyrazol-1-yl) nicotinamida derivatives and their use as phd inhibitors
GB201504565D0 (en) 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
US11510917B2 (en) 2016-02-19 2022-11-29 Cornell University HIF-stabilization and prevention of hyperoxia-induced neonatal lung disease
CN106831735B (zh) 2017-01-23 2019-10-11 牡丹江医学院 一种治疗骨质疏松的杂环化合物及其制备方法和用途
CN109879804B (zh) 2019-01-30 2022-06-17 中国药科大学 5-杂环取代吡啶-2-甲酰甘氨酸化合物、其制法和医药用途
EP4121425A1 (en) 2020-03-20 2023-01-25 Akebia Therapeutics Inc. Phd inhibitor compounds, compositions, and use
KR20220156890A (ko) 2020-03-20 2022-11-28 아케비아 테라퓨틱스 인코포레이티드 Phd 억제제 화합물, 조성물, 및 용도
AR121626A1 (es) 2020-03-20 2022-06-22 Akebia Therapeutics Inc Compuestos inhibidores de phd, composiciones y métodos de uso
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
EP4196466A1 (en) 2020-08-14 2023-06-21 Akebia Therapeutics Inc. Phd inhibitor compounds, compositions, and methods of use

Similar Documents

Publication Publication Date Title
JP2023518262A5 (cg-RX-API-DMAC10.html)
JP2023540228A5 (cg-RX-API-DMAC10.html)
JP2023171659A5 (cg-RX-API-DMAC10.html)
JP2005514420A5 (cg-RX-API-DMAC10.html)
JP2024509818A5 (cg-RX-API-DMAC10.html)
CA2820109C (en) Pyridine amide derivatives as ep4 receptor antagonists
JP2021169499A5 (cg-RX-API-DMAC10.html)
JP2021514001A5 (cg-RX-API-DMAC10.html)
JP2020523351A5 (cg-RX-API-DMAC10.html)
JP2007524696A5 (cg-RX-API-DMAC10.html)
TW200519092A (en) Malonamide derivatives
JP2012529535A5 (cg-RX-API-DMAC10.html)
JP2023518953A5 (cg-RX-API-DMAC10.html)
JP2002516314A5 (cg-RX-API-DMAC10.html)
JP2010538076A5 (cg-RX-API-DMAC10.html)
JP2021529814A5 (cg-RX-API-DMAC10.html)
JP2023531709A5 (cg-RX-API-DMAC10.html)
JP2024529527A5 (cg-RX-API-DMAC10.html)
JP2008510828A5 (cg-RX-API-DMAC10.html)
JP2019500315A5 (cg-RX-API-DMAC10.html)
JP2005511545A5 (cg-RX-API-DMAC10.html)
JP2021528451A5 (cg-RX-API-DMAC10.html)
AR041855A1 (es) 4 amino-1- (piridilmetil) piperidina sustituida y compuestos relacionados
JP2022533939A5 (cg-RX-API-DMAC10.html)
JP2023531495A5 (cg-RX-API-DMAC10.html)